Figure 3. Box plot illustrating the distribution of enhanced CT value (A-C), 68Ga-PSMA-11 (D-F) and 18F-FDG PET/CT SUVmax (G-I) according to the pathological features of ccRCC. The pathological characteristics include tumor necrosis (A, D, G), sarcomatoid or rhabdoid differentiation (B, E, H) and adverse pathology (C, F, I). Adverse pathology is defined as a tumor presenting with necrosis or a sarcomatoid or rhabdoid feature; SUVmax, maximum standardized uptake value; CT, computed tomography; ccRCC, clear-cell renal cell carcinoma.
